

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-047US1	Application No. 10/573,196
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Brian Smith et al.	
		Filing Date March 29, 2007	Group Art Unit 1.624
(37 CFR §1.98(b))			

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/B.C./	A1	US 3652543	3/28/72	Hoegerle	540	594	
/B.C./	A2	US 3716639	2/13/73	Hoegerle et al.	514	217 . 01	
/B.C./	A3	US 3795683	3/05/74	Brossi et al.	540	586	
/B.C./	A4	US 4108989	8/22/78	Holden	514	217 . 01	
/B.C./	A5	US 4111957	9/05/78	Holden et al.	540	594	
/B.C./	A6	US 4210749	7/01/80	Shetty	540	594	
/B.C./	A7	US 4210729	7/01/80	Bola V. Shetty	525	247	
/B.C./	A8	US 4233217	11/11/80	Shetty	540	594	
duplicate	A9	US 5387685	2/07/85	Powell et al.			
/B.C./	A10	US 4762845	8/09/88	Chu et al.	514	312	
/B.C./	A11	US 4988690	1/29/91	Efland et al.	514	217 . 01	
/B.C./	A12	US 5015639	5/14/91	Berger et al.	514	210 . 21	
/B.C./	A13	US 5178786	1/12/93	Jahnke et al.	252	77	
/B.C./	A14	US 5387685	7/16/93	Powell et al.	546	143	
/B.C./	A15	US 5275915	1/04/94	Kojima et al.	430	264	
/B.C./	A16	US 5412119	5/02/95	Brussee et al.	549	419	
/B.C./	A17	US 5422355	6/06/95	White et al.	514	311	
/B.C./	A18	US 5691362	11/25/97	McCormick et al.	514	339	
/B.C./	A19	US 5750520	5/12/98	Danilewicz et al.	514	212	
/B.C./	A20	US 5856503	1/05/99	Aebi et al.	548	207	
/B.C./	A21	US 5861393	1/19/99	Danilewicz et al.	514	213	
/B.C./	A22	US 5925651	7/20/99	Hutchinson	514	307	
/B.C./	A23	US 5939415	8/17/99	Laufer et al.	514	224 . 2	
/B.C./	A24	US 5942535	8/24/99	Laufer et al.	514	413	
/B.C./	A25	US 5958943	9/28/99	Laufer et al.	514	299	
/B.C./	A26	US 6087346	7/11/00	Glennon et al.	514	65	
duplicate	A27	US 6218285	4/17/01	Adam et al.			

Examiner Signature /Brenda Coleman/	Date Considered 09/23/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-047US1	Application No. 10/573,196
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Brian Smith et al.	
		Filing Date March 29, 2007	Group Art Unit 1 624
(37 CFR §1.98(b))			

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/B.C./	A28	US 6218385	4/17/01	Geo Adam et al.	514	217 . 01	
/B.C./	A29	US 6900313	5/31/05	Wasserscheid et al.	544	59	
/B.C./	A30	US 6953787	10/11/05	Smith et al.	514	212 . 02	
/B.C./	A31	US 6972295	12/06/05	Hagmann et al.	514	345	
/B.C./	A32	2008/0009478	01/10/08	Smith et al.	514	217 . 01	

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
** /B.C./	A33	DE 1944121	3/19/70	Germany				
** /B.C./	A34	CH 500194	1/29/71	Switzerland				
/B.C./	A35	GB 1221324	2/03/71	United Kingdom				
/B.C./	A36	GB 1225053	3/17/71	United Kingdom				
/B.C./	A37	GB 1268243	3/22/72	United Kingdom				
** /B.C./	A38	NL 7807819	7/21/78	Netherlands				
/B.C./	A39	EP 0007070	1/23/80	Europe				
/B.C./	A40	CA 1090797	12/02/80	Canada				
/B.C./	A41	GB 1599705	10/07/81	United Kingdom				
/B.C./	A42	EP 0080779 A1	6/08/83	Europe				
/B.C./	A43	DE 3315106 A1	11/03/83	Germany				
/B.C./	A44	EP 0096838 A1	12/28/83	Europe				
/B.C./	A45	EP 0161350 A1	11/21/85	Europe				
/B.C./	A46	EP 0174118 A2	3/12/86	Europe				
/B.C./	A47	EP 0285287 A3	3/23/87	Europe				
/B.C./	A48	EP 0285919	10/12/88	Europe				
/B.C./	A49	WO 8807858	10/20/88	WIPO				
/B.C./	A50	WO 9119698	12/26/91	WIPO				
/B.C./	A51	WO 9300094	1/07/93	WIPO				

Examiner Signature /Brenda Coleman/	Date Considered 09/23/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-047US1	Application No. 10/573,196
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Brian Smith et al.	
		Filing Date March 29, 2007	Group Art Unit 1 62 4
(37 CFR §1.98(b))			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
** /B.C./	A52	JP 5339263	12/21/93	Japan				
** /B.C./	A53	JP 06298746	10/25/94	Japan				
/B.C./	A54	WO 9513274	5/18/95	WIPO				
/B.C./	A55	CA 2197789	8/16/95	Canada				
** /B.C./	A56	WO 9604271	2/15/96	WIPO				
** /B.C./	A57	WO 9605194	2/22/96	WIPO				
** /B.C./	A58	JP 08134048	5/28/96	Japan				
/B.C./	A59	WO 9633993	10/31/96	WIPO				
/B.C./	A60	JP 09030960	2/04/97	Japan				
/B.C./	A61	JP 90987258	3/31/97	Japan				
/B.C./	A62	WO 97/24364	7/10/97	WIPO				
/B.C./	A63	WO 9806701	2/19/98	WIPO				
/B.C./	A64	WO 9840385	9/17/98	WIPO				
/B.C./	A65	WO 99/24411	5/20/99	WIPO				
duplicate	A66	EP 0987235 A1	3/22/00	Europe				
/B.C./	A67	EP 1074549 A2	2/07/01	Europe				
/B.C./	A68	WO 0240471	5/23/02	WIPO				
/B.C./	A69	WO 0248124	6/20/02	WIPO				
** /B.C./	A70	WO 02074746	9/26/02	WIPO				
/B.C./	A71	WO 03000663	1/03/03	WIPO				
/B.C./	A72	WO 2003/027068	4/03/03	WIPO				
/B.C./	A73	WO 2003/062392	7/31/03	WIPO				
/B.C./	A74	WO 03086306	10/23/03	WIPO				
/B.C./	A75	EP 987235	12/03/03	Europe				
/B.C./	A76	WO 04037788	5/06/04	WIPO				
/B.C./	A77	WO2005/003096A1	01/13/2005	PCT				
/B.C./	A78	WO2005/019179A2	03/03/2005	PCT				

Examiner Signature /Brenda Coleman/	Date Considered 09/23/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-047US1	Application No. 10/573,196
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Brian Smith et al.	
		Filing Date March 29, 2007	Group Art Unit 1 624
(37 CFR §1.98(b))			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/B.C./	A79	WO2005/042491A1	05/12/2005	PCT				
/B.C./	A80	WO 2006/013209	2/09/2006	WIPO				
** /B.C./	A81	WO 2006/043710	4/27/2006	WIPO				
/B.C./	A82	WO2006/069363A2	06/29/06	WIPO				
/B.C./	A83	WO2006/071740A2	07/06/06	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/B.C./	A84	Barnes, T. R., "Pharmacological Strategies for Relapse Prevention in Schizophrenia", <i>Psychiatry</i> 3(10): 37-40 (2004)
/B.C./	A85	Chahal et al., IDdb Meeting Report 2000, May 17-18
/B.C./	A86	Chang et al., "Dopamine receptor binding properties of some 2, 3, 4, 5-tetrahydro-1H-3-benzazepine-7-ols with non-aromatic substituents in the 5-position", <i>Bioorg. Med. Chem. Lett.</i> 2:399-402 (1992)
/B.C./	A87	Deady et al., "Synthesis of some tetrahydro-2-and 3-benzazepines, and of hexahydro-3-benzazocine", <i>Journal of the Chemical Society, Perkins Transactions</i> 1, 1973 pp. 782-783
/B.C./	A88	Di Chiara G., (2002) <i>Behavioural Brain Research</i> , 137: 75-114
/B.C./	A89	Di Chiara et al., "Reward System and Addiction: What Dopamine Does and Doesn't Do", <i>Current Opinion in Pharmacology</i> 7:69-76 (2007)
	A90	Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision, Washington, DC: American Psychiatric Association, 2000*
/B.C./	A91	Di Matteo et al., "Role of 5-HT _{2C} Receptors in the Control of Central Dopamine Function", <i>Trends in Pharmacological Sciences</i> 22(5):229-232 (2001)
/B.C./	A92	Flannery-Schroeder, E. C., "Reducing Anxiety to Prevent Depression", <i>Am. J. Prev. Med.</i> 31(6S1):S136-S142 (2006)
/B.C./	A93	Fuchs et al., "Total synthesis of (+/-)-lennoxamine and (+/-)-aphanorphone by intramolecular electrophilic aromatic substitution reactions of 2-amidoacroleins", <i>Organic Letters</i> , 2001, pp. 3923-3925, 3(24) American Chemical Society
/B.C./	A94	Gallant et al., (1967) <i>Current Therapy Research</i> 9(11):579-81
** /B.C./	A95	Gardent et al., "Sur quelques de l' amino-2-bromo-4 1H benzazepine-3 et de ses derives", <i>Bull Soc. Chim. France</i> 2:600-605 (1968)
/B.C./	A96	Gerace et al., "Predictors of Weight Increases over 7 Years in Fire Fighters and Paramedics", <i>Preventive Medicine</i> 94:593-600 (1996)
/B.C./	A97	Gobert et al., (2000) <i>Synapse</i> 36: 205-221
/B.C./	A98	Gombar et al., "Pharmacokinetics of a series of 6-chloro-2, 3, 4, 5-tetrahydro-3-substituted-1H-3-benzazepines in rats", <i>Drug Metab. Disposition</i> 16:367-372 (1988)

Examiner Signature /Brenda Coleman/	Date Considered 09/23/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-047US1	Application No. 10/573,196
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Brian Smith et al.	
		Filing Date March 29, 2007	Group Art Unit 1624
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	A99	<u>Groene et al., Protective Groups in Organic Syntheses, 2nd Ed., Wiley and Sons, NY (1991)*</u>
/B.C./	A100	Halford et al., "Serotonergic Drugs: Effects on Appetite Expression and Use for the Treatment of Obesity", <i>Drugs</i> 67(1):27-55 (2007)
/B.C./	A101	Halford, J.C.G., "Obesity Drugs in Clinical Development", <i>Current Opinion in Investigational Drugs</i> 7(4):312-318 (2006)
** /B.C./	A102	Hassine-Coniac et al., "Préparation et propriétés d'aldéhydes dans la série de la benzazapine-3", <i>Bull Soc. Chim. France</i> 11:3985-3992 (1971)
** /B.C./	A103	Hazebrucq, "Accès a des I-H, tétrahydro-2, 3, 4, 5 benzazépines-3 one-1 et a des hexahydro imidazo isoquinolines", <i>Ann. Chim.</i> (1966) pp. 221-254
/B.C./	A104	Hester et al., (1968) <i>J. Med. Chem.</i> 11(1): 101
/B.C./	A105	Higgins et al., (2003) <i>European Journal of Pharmacology</i> , 480: 151
/B.C./	A106	Hitzig, P., (1994) <i>Journal of Substance Abuse Treatment</i> , 11(5): 489
/B.C./	A107	Im et al., (2003) <i>Molecular Pharmacology</i> , 64: 78-84
/B.C./	A108	Jandacek, R.J., "APD-356 (Arena)", <i>Current Opinion in Investigational Drugs</i> 6(10):1051-1056 (2005)
/B.C./	A109	Jenck et al., (1998) <i>European Neuropsychopharmacology</i> 8: 161
/B.C./	A110	Jensen et al., "Potential Role of New Therapies in Modifying Cardiovascular Risk in Overweight Patients with Metabolic Risk Factors", <i>Obesity</i> 14 (Suppl. 3):143S-149S (2006)
/B.C./	A111	Karasu et al., (2000) Practice Guideline for the Treatment of Patients with Major Depressive Disorder 1-78
/B.C./	A112	Koplan et al., "Preventing Childhood Obesity: Health in the Balance, Executive Summary", http://www.nap.edu/catalog/11015.html , 41 pages (2005)
/B.C./	A113	Krull, O. and Wunsh, B., "Synthesis and Structure/NMDA Receptor Affinity Relationships of 1-Substituted Tetrahydro-3-benzazepines", <i>Bioorganic and Medicinal Chemistry</i> , 12, pp. 1439-1451, 2004.
/B.C./	A114	Ladd et al., "Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 2-benzazepines, and 9-(Aminomethyl) fluorenes", <i>J. Med. Chem.</i> , Vol. 29:1904-1912 (1986)
/B.C./	A115	Lam RW, Levitt AJ (1999) (eds) Canadian Consensus Guidelines for the Treatment of Seasonal Affective Disorder, Clinical & Academic Publishing, Vancouver, BC, Canada
/B.C./	A116	Lennon et al., "Azabenzocycloheptenones Part XVIII. Amines and amino-ketones of the tetrahydro-3-benzazepine-1-one series", <i>J. Chem. Soc. Perkin Transacts.</i> (1975) 7:622-626
/B.C./	A117	Linda D. Williams, <i>Chemistry Demystified</i> 123 (2003)
/B.C./	A118	Maddonald et al., "Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))-phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): A Potent and selective dopamine D.sub.3 Receptor Antagonist", <i>J. Med. Chem.</i> 46:4952-4964 (2003) American Chemical Society
/B.C./	A119	Moline et al., (2001) Expert Consensus Guideline Series - Treatment of Depression in Women 2001, March: 112-113
/B.C./	A120	Müller et al., (2006) <i>Trends in Pharmacological Sciences</i> , 27(9): 455 (Abstract)

Examiner Signature /Brenda Coleman/	Date Considered 09/23/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-047US1	Application No. 10/573,196
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Brian Smith et al.	
		Filing Date March 29, 2007	Group Art Unit 1 62 4
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	A121	National Institute on Drug Abuse, Proceedings of the 41st Annual Scientific Meeting (1979) pp. 356-401
/B.C./	A122	Navarro-Vazquez et al., "A study of aryl radical cyclization in enaminone esters", J. Org. Chem. 67:3213-20 (2002)
/B.C./	A123	Niendam et al., "Neurocognitive Performance and Functional Disability in the Psychosis Prodrome", <i>Schizophrenia Research</i> 84:100-111 (2006)
/B.C./	A124	Orioto et al., "Benzolactams—I: Alkylation of 1,2,4,5-tetrahydro-3-methyl-3H-benzazepine-2-one with sodium hydride and alkyl halide", <i>Tetrahedron</i> 36:1017-1021 (1980) Pergamon Press Ltd.
/B.C./	A125	Orito et al. (Hokkaido Daigaku Kokagaku Kenkyu Hokoku (1979), (96), 41-44
/B.C./	A126	Orito et al., "Total synthesis of pseudo type of protopine alkaloids", <i>Heterocycles</i> 14(1) 1980
/B.C./	A127	Pauvert et al., "Silver nitrate-promoted ring enlargement of 1-tribromomethyl-1,2-dihydro- and 1-tribromomethyl-1,2,3,4-tetrahydro-isoquinoline derivatives: application to the synthesis of the anti-anigal zalebradine", <i>Tetrahedron Letters</i> 44:4203-4206 (2003) Pergamon Press Ltd.
/B.C./	A128	Pawan et al., (1971) <i>British Journal of Pharmacology</i> , 41(2): 416P-417P (CAPLUS abstract)
/B.C./	A129	Pecherer et al., "The Synthesis of Some 7- and 8-substituted 2,3,4,5-tetrahydro-1H-3benzazepines", <i>J. Heterocyclic Chemistry</i> 8(5):779-783 (1971)
/B.C./	A130	Perry et al., "Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men", <i>BMJ</i> (1995) 310:560-564
/B.C./	A131	Piesla et al., (2001) <i>Schizophrenia Research</i> 49: 95
/B.C./	A132	Porras et al., (2002) <i>Neuropsychopharmacology</i> 26: 311-324
/B.C./	A133	Prous Science Integrity entry 156186 1954
/B.C./	A134	Prous Science Integrity entry 354056 2003
/B.C./	A135	Rothman R.B., (1995) <i>Journal of Substance Abuse Treatment</i> , 12(6): 449
/B.C./	A136	Schladerman et al., "Synthesis of oxo- and 1-hydroxy-azobenzocycloalkanes", <i>J. Chem. Soc. Perkin Transacts</i> , (1972) 2:213-215
/B.C./	A137	Schaffner et al., "Preventing Severe Mental Illnesses – New Prospects and Ethical Challenges", <i>Schizophrenia Research</i> 51:3-15 (2001)
/B.C./	A138	Smith et al., "Discovery and SAR of New Benzazepines as Potent and Selective 5-HT _{2C} Receptor Agonists for the Treatment of Obesity", <i>Bioorganic & Medicinal Chemistry Letters</i> 15(5):1467-1470 (2005)
/B.C./	A139	Smith, B. M. et al., "Discovery and Structure – Activity Relationship of (1R)-8-Chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a Selective Serotonin 5-HT _{2C} Receptor Agonist for the Treatment of Obesity", [retrieved on 12/21/07]. Retrieved from the Internet. <URL: http://pubs.acs.org/journals/jmcmar/index.html >.
/B.C./	A140	Tietz et al., "Efficient synthesis of 2, 3, 4, 5-tetrahydro-1H-3-benzazepines by intramolecular Heck reaction", <i>Synthesis</i> (1993) 9:876-880

Examiner Signature /Brenda Coleman/	Date Considered 09/23/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-047US1	Application No. 10/573,196
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Brian Smith et al.	
		Filing Date March 29, 2007	Group Art Unit 1624

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/B.C./	A141	Tietze et al., "Efficient synthesis of 2,3,4,5-tetrahydro-1H-3-benzazepines by intramolecular heck reaction", Institut für Organische Chemie der Universität Göttingen, Tammannstraße 2, D-3400 Göttingen, Germany, received January 29, 1993.
/B.C./	A142	Tsuang et al., "Towards the Prevention of Schizophrenia", <i>Biol. Psychiatry</i> 48:349-356 (2000)
/B.C./	A143	Vink et al., "Risk Factors for Anxiety and Depression in the Elderly: A Review", <i>J. Affect. Disord.</i> , doi:10.1016/j.jad.2007.06.005, 16 pages (2007)
/B.C./	A144	Wise, R.A., (2000) <i>Neuron</i> , 26: 27-33
/B.C./	A145	Wisner et al., (2002) <i>N. Engl. J. Med.</i> , 347(3): 194-199
/B.C./	A146	Yoshinaga et al., "Prevention of Mildly Overweight Children from Development of More Overweight Condition", <i>Preventive Medicine</i> 38:172-174 (2004)
/B.C./	A147	International Search Report dated <u>March 15, 2005</u> for International Application No. PCT/US2004/034914.

Examiner Signature /Brenda Coleman/	Date Considered 09/23/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	